I want to donate

The Haematology research group at the IDIBGI started in 2007 as an extension of the haematology service at ICO Girona. The group is dedicated to clinical and translational studies in relation to diagnostic, prognostic, and therapeutic processes in hemopathies, the group is made up of haematologists, nurses, biologists and technicians.

Main lines of research
  • Study genetic variants involved in the immune response as survival predictors and graft disease against the host after allogenic transplantation of hematopoietic progenitors.
  • Study biological and pharmacogenomic aspects associated with response to the treatment of acute myeloblastic leukaemia
  • Analysis of genetic polymorphisms as predictors of multiple myeloma progression.
  • Study of genetic polymorphisms involved in evolution and the response to treatment of chronic lymphatic leukaemia.
  • Study of cell populations using flow cytometry for the characterization of hemopathies and detection of residual disease.
Strategic objectives
  • To investigate biological, clinical, and epidemiological aspects of haematological diseases
  • To carry out translational research projects focused on finding prognostic factors or treatment response predictors
  • To carry out clinical research, promoting participation in clinical trials for haematological diseases and participating in national or international cooperative groups.
Publications

Alvarez-Larrán A, Angona A, Andrade-Campos M, Soledad Noya M, Teresa Gómez-Casares M, Cuevas B, Caballero G, García-Hernández C, García-Gutiérrez V, Palomino A, Ferrer-Marín F, Isabel Mata-Vázquez M, Moretó A, Magro E, Murillo I, Manuel Alonso-Domínguez J, María Guerra J, Guerrero L, María Raya J, Pérez-Encinas M, Carreño-Tarragona G, Fox L, Pastor-Galán I, Bellosillo B, Hernández-Boluda JC, MPN Spanish Group (GEMFIN)

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192, 988-996 dx.doi.org/10.1111/bjh.16988

Villavicencio A, Solans M, Zacarías-Pons L, Vidal A, Puigdemont M, Roncero JM, Saez M, Marcos-Gragera R

Comorbidities at Diagnosis, Survival, and Cause of Death in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18, 701 dx.doi.org/10.3390/ijerph18020701

Negre Busó M, Balliu Collgrós E, Ferran Sureda N, Velasco Nuño M, Roncero Vidal JM, Rubió Rodríguez A

Follicular dendritic cell tumor in the context of a Castleman disease in a patient with Diffuse Large B Cell Lymphoma: Diagnosis and follow-up with 18 F-FDG PET/CT.

REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2021, 40, 322-324 dx.doi.org/10.1016/j.remn.2020.06.011

Negre Busó M, Balliu Collgrós E, Rubió Rodríguez A, Peláez Hernández I, Mestre Fusco A, Roncero Vidal JM

Utility of the (18)F-FDG PET/CT in the diagnosis of the neurolymphomatosis: a case report.

REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2020, 40, 328-331 dx.doi.org/10.1016/j.remn.2020.06.021

Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D, on the behalf of CETLAM Group

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.

Leukemia, 2020, 34, 2925-2933 dx.doi.org/10.1038/s41375-020-0784-2

Villavicencio A, Solans M, Auñon-Sanz C, Roncero JM, Marcos-Gragera R

Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain.

CANCER EPIDEMIOLOGY, 2020, 69, 101841-101841 dx.doi.org/10.1016/j.canep.2020.101841

Pastor-Galán I, Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F, en representación del Grupo Español de Enfermedades Mieloproliferativas Filadelf

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.

MEDICINA CLINICA, 2020, 155, 152-158 dx.doi.org/10.1016/j.medcli.2019.11.007

Parody R, Sánchez-Ortega I, Ferrá C, Guardia R, Talarn C, Encuentra M, Fort E, López D, Morgades M, Alonso E, Ortega S, Sarrá J, Gallardo D, Ribera JM, Sureda A

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis.

Oncology And Therapy, 2020, 8, 311-324 dx.doi.org/10.1007/s40487-020-00115-3

Sitges M, Boluda B, Garrido A, Morgades M, Granada I, Barragan E, Arnan M, Serrano J, Tormo M, Miguel Bergua J, Colorado M, Salamero O, Esteve J, Benavente C, Pérez-Encinas M, Coll R, Martí-Tutusaus JM, Brunet S, Sierra J, Ángel Sanz M, Montesinos P, Ribera JM, Vives S, PETHEMA, CETLAM cooperative groups

Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols.

EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105, 138-147 dx.doi.org/10.1111/ejh.13417

Hyvärinen K, Koskela S, Niittyvuopio R, Nihtinen A, Volin L, Salmenniemi U, Putkonen M, Buño I, Gallardo D, Itälä-Remes M, Partanen J, Ritari J

Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD.

Frontiers in Immunology, 2020, 11, 19-19 dx.doi.org/10.3389/fimmu.2020.00019
Competitive projects
Codi oficial: PI17/00815 Start date:01/01/2018 Data fi: 30/06/2022 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 104,665 €
Codi oficial: EFA281/16 Start date:01/01/2018 Data fi: 31/12/2021 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: CONSORCIO DE LA CTP. INTERREG POCTEFA Ajuda: 152,425.64 €
Codi oficial: PI20/01353 Start date:01/01/2021 Data fi: 31/12/2023 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 135,520 €
Job offers
Reference 058-2021 | Haematology
Senior Laboratory Technician Data del termini d'inscripció: 20211208

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

menu